TCI Wealth Advisors Inc. Increases Holdings in Eli Lilly and Company (NYSE:LLY)

TCI Wealth Advisors Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,101 shares of the company’s stock after acquiring an additional 637 shares during the period. Eli Lilly and Company comprises 0.5% of TCI Wealth Advisors Inc.’s holdings, making the stock its 29th largest position. TCI Wealth Advisors Inc.’s holdings in Eli Lilly and Company were worth $4,722,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Sage Mountain Advisors LLC grew its holdings in Eli Lilly and Company by 5.2% during the third quarter. Sage Mountain Advisors LLC now owns 4,169 shares of the company’s stock worth $2,239,000 after acquiring an additional 206 shares during the period. Sawyer & Company Inc grew its holdings in Eli Lilly and Company by 0.4% in the third quarter. Sawyer & Company Inc now owns 6,710 shares of the company’s stock valued at $3,604,000 after purchasing an additional 25 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its holdings in Eli Lilly and Company by 13.1% in the third quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 68,290 shares of the company’s stock valued at $36,681,000 after purchasing an additional 7,894 shares during the period. Vantage Investment Partners LLC grew its holdings in Eli Lilly and Company by 2.2% in the third quarter. Vantage Investment Partners LLC now owns 31,114 shares of the company’s stock valued at $16,712,000 after purchasing an additional 656 shares during the period. Finally, Lathrop Investment Management Corp grew its holdings in Eli Lilly and Company by 1.2% in the third quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after purchasing an additional 18 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on the company. BMO Capital Markets raised their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Finally, The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Shares of LLY stock traded down $20.94 on Friday, hitting $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The firm has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The company’s 50 day moving average price is $761.06 and its 200-day moving average price is $672.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 EPS. Analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.